PHENYLBUTAZONE SODIUM

US Previously Marketed

Details

Stereochemistry	ACHIRAL
Molecular Formula	C19H19N2O2.Na
Molecular Weight	330.3561
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[Na+].CCCC[C-]1C(=O)N(N(C1=O)C2=CC=CC=C2)C3=CC=CC=C3

InChI

InChIKey=VYOUHDLOIRJOSW-UHFFFAOYSA-N

InChI=1S/C19H19N2O2.Na/c1-2-3-14-17-18(22)20(15-10-6-4-7-11-15)21(19(17)23)16-12-8-5-9-13-16;/h4-13H,2-3,14H2,1H3;/q-1;+1

HIDE SMILES / InChI

Molecular Formula	C19H20N2O2
Molecular Weight	308.3743
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	Na
Molecular Weight	22.9898
Charge	1
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/796939 | https://www.ncbi.nlm.nih.gov/pubmed/14927431

Phenylbutazone is an anti-inflammatory drug, which binds to and inactivates cyclooxygenases and prostacyclin synthase through peroxide (H2O2) mediated deactivation. The reduced production of prostaglandin leads to reduced inflammation of the surrounding tissues. Phenylbutazone was marked under the brand name butazolidin for the treatment rheumatoid arthritis and gout, but then this usage was discontinued. In addition, phenylbutazone is used in UK for the treatment of ankylosing spondylitis, but only in those cases, when other therapies are unsuitable.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Prostacyclin synthase 4 Target ID: Q16647 Gene ID: 5740.0 Gene Symbol: PTGIS Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/3917545	Inhibitor 8297
Cyclooxygenase 89 Target ID: CHEMBL2094253 Sources: https://www.ncbi.nlm.nih.gov/pubmed/809810	Inhibitor 8297

Conditions

Condition	Modality	Highest Phase	Product
Ankylosing spondylitis 33 Sources: https://www.ncbi.nlm.nih.gov/pubmed/12381510	Primary	Approved 8429	Unknown Approved Use Unknown
Gout 28 Sources: https://www.ncbi.nlm.nih.gov/pubmed/14927431	Palliative	Approved 8429	BUTAZOLIDIN Approved Use Unknown
Rheumatoid arthritis 316 Sources: https://www.ncbi.nlm.nih.gov/pubmed/14927431	Palliative	Approved 8429	BUTAZOLIDIN Approved Use Unknown

Doses

Dose	Population	Adverse events
8 g single, oral Overdose Dose: 8 g Route: oral Route: single Dose: 8 g Sources: https://pubmed.ncbi.nlm.nih.gov/7427601	healthy, 17 years n = 1 Health Status: healthy Age Group: 17 years Sex: F Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/7427601	Other AEs: Renal disorder NOS, Jaundice... Other AEs: Renal disorder NOS Jaundice Sources: https://pubmed.ncbi.nlm.nih.gov/7427601
800 mg 1 times / day multiple, oral Highest studied dose Dose: 800 mg, 1 times / day Route: oral Route: multiple Dose: 800 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/3907678	unhealthy, 52.8 years (range: 24-89 years) Health Status: unhealthy Condition: acute gouty arthritis Age Group: 52.8 years (range: 24-89 years) Sources: https://pubmed.ncbi.nlm.nih.gov/3907678	Other AEs: Rash, Dyspepsia... Other AEs: Rash (1 patient) Dyspepsia (1 patient) Constipation (2 patients) Sleepiness (1 patient) Irritability (1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/3907678

AEs

AE	Significance	Dose	Population
Jaundice		8 g single, oral Overdose Dose: 8 g Route: oral Route: single Dose: 8 g Sources: https://pubmed.ncbi.nlm.nih.gov/7427601	healthy, 17 years n = 1 Health Status: healthy Age Group: 17 years Sex: F Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/7427601
Renal disorder NOS		8 g single, oral Overdose Dose: 8 g Route: oral Route: single Dose: 8 g Sources: https://pubmed.ncbi.nlm.nih.gov/7427601	healthy, 17 years n = 1 Health Status: healthy Age Group: 17 years Sex: F Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/7427601
Dyspepsia	1 patient	800 mg 1 times / day multiple, oral Highest studied dose Dose: 800 mg, 1 times / day Route: oral Route: multiple Dose: 800 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/3907678	unhealthy, 52.8 years (range: 24-89 years) Health Status: unhealthy Condition: acute gouty arthritis Age Group: 52.8 years (range: 24-89 years) Sources: https://pubmed.ncbi.nlm.nih.gov/3907678
Irritability	1 patient	800 mg 1 times / day multiple, oral Highest studied dose Dose: 800 mg, 1 times / day Route: oral Route: multiple Dose: 800 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/3907678	unhealthy, 52.8 years (range: 24-89 years) Health Status: unhealthy Condition: acute gouty arthritis Age Group: 52.8 years (range: 24-89 years) Sources: https://pubmed.ncbi.nlm.nih.gov/3907678
Rash	1 patient	800 mg 1 times / day multiple, oral Highest studied dose Dose: 800 mg, 1 times / day Route: oral Route: multiple Dose: 800 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/3907678	unhealthy, 52.8 years (range: 24-89 years) Health Status: unhealthy Condition: acute gouty arthritis Age Group: 52.8 years (range: 24-89 years) Sources: https://pubmed.ncbi.nlm.nih.gov/3907678
Sleepiness	1 patient	800 mg 1 times / day multiple, oral Highest studied dose Dose: 800 mg, 1 times / day Route: oral Route: multiple Dose: 800 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/3907678	unhealthy, 52.8 years (range: 24-89 years) Health Status: unhealthy Condition: acute gouty arthritis Age Group: 52.8 years (range: 24-89 years) Sources: https://pubmed.ncbi.nlm.nih.gov/3907678
Constipation	2 patients	800 mg 1 times / day multiple, oral Highest studied dose Dose: 800 mg, 1 times / day Route: oral Route: multiple Dose: 800 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/3907678	unhealthy, 52.8 years (range: 24-89 years) Health Status: unhealthy Condition: acute gouty arthritis Age Group: 52.8 years (range: 24-89 years) Sources: https://pubmed.ncbi.nlm.nih.gov/3907678

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
inducer 781	inhibitor 1767

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
OAT1 599 OAT3 642 OAT4 146 MRP4 204 BCRP 699 MRP2 383 UGT1A6 108

Drug as perpetrator

Target	Modality	Activity
MRP2 475	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/17578901/ Page: 5.0	no
BCRP 773	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/17578901/ Page: 5.0	partial
CYP2C9 1819	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/3355588/	yes [Ki 11 uM]
MRP4 238	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/17578901/ Page: 5.0	yes [Ki 354 uM]
OAT3 644	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/17578901/ Page: 5.0	yes [Ki 6.82 uM]
OAT1 603	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/17578901/ Page: 5.0	yes [Ki 71.6 uM]
CYP3A4 1925	inducer 1573 Sources: https://pubmed.ncbi.nlm.nih.gov/10219967/	yes
OAT4 146	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/12130730/ Page: 1.0	yes
UGT1A6 141	inhibitor 3277 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6067388/	yes

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:48574	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:48574
ChemicalBook	CB0370134	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB0370134
MolPort	MolPort-001-783-564	https://www.molport.com/shop/molecule-link/MolPort-001-783-564
Selleck Chemicals	Phenylbutazone(Butazolidin)	http://www.selleckchem.com/products/Phenylbutazone(Butazolidin).html
ZINC	ZINC000100004227	http://zinc15.docking.org/substances/ZINC000100004227
eMolecules	27523332	https://www.emolecules.com/cgi-bin/more?vid=27523332
eMolecules	593834	https://www.emolecules.com/cgi-bin/more?vid=593834

PubMed

Title	Date	PubMed
Phenylbutazone-induced pericarditis.	1965 Oct 2	5825420
[The renal incidents of phenylbutazone].	1966 Dec 3	5924165
[Renal complications following phenylbutazone treatment].	1966 May 19	5974146
Phenylbutazone anuria.	1967 Dec	6060746
Nephrotic syndrome caused by probenecid.	1967 Jan 2	6071127
Bone marrow depression induced by chloramphenicol or phenylbutazone. Leukemia and other sequelae.	1967 Sep 11	6071896
Probenecid, nephrotic syndrome, and renal failure.	1968 May	5655316
[A fatal pathological condition with hyperglobulinemic purpura and polymyositis after phenylbutazone].	1968 Nov 15	5755571
Rheumatoid arthritis: comparison of treatment with monophenylbutazone and phenylbutazone.	1969 Dec 27	4903691
Treatment of aplastic anemia with nandrolone decanoate.	1970 Dec	5485118
Mefanamic acid-induced haemolytic anaemia.	1970 May 2	5420190
[Allergo-toxic disturbances of the heart muscle with congestive heart failure as a result of parenteral treatment with phenylbutazone].	1971 Feb	5546848
Papillary necrosis following phenylbutazone ingestion.	1971 Sep	5569932
[Acute renal insufficiency following butapyrazole treatment in the course of plasmatic cell leukemia (author's transl)].	1973	4779657
[Primary cardiac involvement and painful salivary gland enlargement due to phenylbutazone].	1974 Mar 1	4830208
Aspirin and the kidney. New Zealand Rheumatism Association Study.	1974 Mar 30	4821007
Double-bind cross-over tiral of flurbiprofen and phenylbutazone in ankylosing spondylitis.	1974 Nov 30	4611579
Renal and gastric lesions after phenylbutazone and indomethacin in the rat.	1974 Oct	4548752
Letter: Idiosyncrasy to phenothiazines in phenylbutazone-associated aplastic anaemia.	1974 Oct 5	4425837
Proceedings: A pharmacokinetic study of phenylbutazone-associated hypoplastic anaemia.	1974 Sep	4415226
Further studies of the acute effects of phenylbutazone, oxyphenbutazone and indomethacin on the rat kidney.	1976 Apr	972771
Aplastic anemia from veterinary phenylbutazone.	1976 Aug 30	989582
Development of a lymphocytic lymphoma during immunosuppressive therapy with azathioprine for systemic lupus erythematosus with renal involvement induced by phenylbutazone.	1977 Jul	577907
Phenylbutazone and the horse--a review.	1977 Jul	330156
Renal papillary necrosis associated with indomethacin and phenylbutazone treated rheumatoid arthritis.	1978 Apr	277165
Exacerbation of phenylbutazone-related renal failure by indomethacin.	1978 Nov	718323
Intrahepatic cholestasis induced by phenylbutazone.	1981	7333419
Acute nephrotic syndrome with reversible renal failure after phenylbutazone.	1981 Mar 21	6781669
Phenylbutazone liver injury: a clinical-pathologic survey of 23 cases and review of the literature.	1981 May-Jun	7286906
Animal experiments on the safety pharmacology of lofexidine.	1982	6890367
Phenylbutazone associated glomerulonephritis. Glomerulonephritis and fever.	1982 Dec	6130055
Sialadenitis and systemic reaction associated with phenylbutazone.	1982 Jun	6214246
Phenylbutazone nephrotoxicity--a light and electron microscopic study.	1983 Dec	6668168
Effects of large doses of phenylbutazone administration to horses.	1983 May	6869982
Renal medullary crest necrosis associated with phenylbutazone therapy in horses.	1983 Nov	6649337
[Nephrotic syndrome and acute interstitial nephritis after phenylbutazone].	1985 Nov 2	2934808
Drug-induced hepatitis associated with anticytoplasmic organelle autoantibodies.	1985 Sep-Oct	4029887
Strain-related susceptibility to nephrotoxicity induced by aspirin and phenylbutazone in rats.	1986	3764320
Risks of agranulocytosis and aplastic anemia. A first report of their relation to drug use with special reference to analgesics. The International Agranulocytosis and Aplastic Anemia Study.	1986 Oct 3	3747087
[Hepatic lesions induced by drugs. Report of 26 cases].	1987	3442185
Dermatomyositis-like syndrome associated with phenylbutazone therapy.	1987 Apr	3599016
Anti-inflammatory activity and sub-acute toxicity of artemetin.	1990 Feb	2356241
Misuse of veterinary phenylbutazone.	1995 Jun 12	7763130
Long-term exposure to the anti-inflammatory agent phenylbutazone induces kidney tumors in rats and liver tumors in mice.	1995 Mar	7744695
Cancer chemopreventive activity of resveratrol, a natural product derived from grapes.	1997 Jan 10	8985016
Development of an in vitro reporter gene assay to assess xenobiotic induction of the human CYP3A4 gene.	1997 Oct-Dec	9512926
Synthesis of biologically active N-methyl derivatives of amidines and cyclized five-membered products of amidines with oxalyl chloride.	2008 Dec	18022734
Genomic biomarkers for cardiotoxicity in rats as a sensitive tool in preclinical studies.	2013 Oct	23558518
FDA-approved drugs and other compounds tested as inhibitors of human glutathione transferase P1-1.	2013 Sep 5	23769903
Phenylbutazone Oxidation via Cu,Zn-SOD Peroxidase Activity: An EPR Study.	2015 Jul 20	26090772

Patents

Sample Use Guides

In Vivo Use Guide

300 mg daily for 4 weeks

Route of Administration: Oral

In Vitro Use Guide

Unknown

Substance Class	Chemical Created by `admin` on `Fri Dec 15 15:08:07 GMT 2023` Edited by `admin` on `Fri Dec 15 15:08:07 GMT 2023`
Record UNII	189M850I32
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

PHENYLBUTAZONE SODIUM

Common Name

English

SODIUM PHENYLBUTAZONE

Common Name

English

3,5-PYRAZOLIDINEDIONE, 4-BUTYL-1,2-DIPHENYL-, ION(1-), SODIUM (1:1)

Common Name

English

ELMEDAL

Brand Name

English

Phenylbutazone sodium [WHO-DD]

Common Name

English

PHENYLBUTAZONE SODIUM SALT [MI]

Common Name

English

PHENYLBUTAZONE SODIUM [MART.]

Common Name

English

SODIUM 4-BUTYL-5-OXO-1,2-DIPHENYL-PYRAZOL-3-OLATE

Systematic Name

English

4-BUTYL-1,2-DIPHENYL-3,5-PYRAZOLIDINEDIONE SODIUM SALT

Common Name

English

Code System Code Type Description

EVMPD

SUB03773MIG